Global Psoriatic Arthritis Therapeutics Market: by Drug Class (NSAIDs, DMARDs, Biologic Drugs, Enzyme Inhibitors, Interleukin Inhibitors), by Disease Type, by Distribution Channel, by Route of Administration - Forecast to 2029

9.5%
CAGR (2023-2029)
7.61 USD Bn.
Market Size
317
Report Pages
144
Market Tables

Overview

Psoriatic Arthritis Therapeutics Market size is expected to reach US$ 15.74 Bn. by year 2029 at a CAGR of 9.5% during the forecast period.

Psoriatic arthritis is a form of arthritis that affects several peoples who have psoriasis. Psoriatic arthritis is an autoimmune disorder that primarily affects psoriasis patients, with nearly 30% of the patient population at risk.

Psoriatic Arthritis Therapeutics Market

To know about the Research Methodology :- Request Free Sample Report

The psoriatic arthritis therapeutics market is primarily driven by a growth in the prevalence of psoriatic arthritis, novel product development and rise in adoption of biologics for the treatment of moderate to simple psoriatic arthritis with unmet medical needs across the globe. Moreover, rising awareness of approximately psoriatic arthritis treatment between the healthcare authorities and developing the elderly population.

Psoriatic Arthritis Therapeutics Market Dynamics:

However, the high cost of the drugs and treatment, and lack of modification tools for diagnosis and procedure are the major restraints in the market. Psoriatic arthritis is an autoimmune disorder, which is temporary as an obstacle for the development of a potential medicine for the suggestion and high treatment costs are challenges in the psoriatic arthritis therapeutics market.

Based on the drug class, the Nonsteroidal anti-inflammatory drug (NSAID) segment is held to dominate the xx% market share during the forecast period. Nonsteroidal anti-inflammatory causes are a collection of medicines that relieve pain and fever and reduce inflammation. NSAIDs are usually the main treatment, NSAIDs are also generally used as an assistant treatment in conjunction with biologics otherwise disease-modifying antirheumatic drugs (DMAD).

The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

The topical segment expected to dominate the xx% market share during the forecast period, owing to the occurrence of improved substitutes with more effective mechanisms of accomplishment. The topical segment normalizes excessive cell reproduction and decreases inflammation caused in psoriasis. There are some effective topical treatments for psoriasis, while many can be procured over the counter (OTC).

Psoriatic Arthritis Therapeutics Market Regional Insights:

Regionally, North America is expected to account for the largest share of the psoriatic arthritis therapeutics market during the forecast period. Owing to increased awareness and growing prevalence of psoriatic arthritis. North America largely is driven by the commercial contracts of products in the United States. Furthermore, the presence of significant establishments, proactive government initiatives, favorable reimbursement policies, and a large patient pool support the psoriatic arthritis treatment market.

The report covers the recent development in the psoriatic arthritis therapeutics market i.e., in November 2018, AbbVie declared patent authorization agreements with Pfizer over its proposed biosimilar adalimumab product. In the terms of the contracts, AbbVie will contribution Pfizer a non-exclusive authorization on specified periods to AbbVie's intelligent assets relating to HUMIRA in the United States and in various other states around the creation in which AbbVie has intellectual assets.

The objective of the report is to present comprehensive analysis of global psoriatic arthritis therapeutics market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding global psoriatic arthritis therapeutics market dynamics, structure by analyzing the market segments, and project the global Psoriatic Arthritis Therapeutics market size. Clear representation of competitive analysis of key players by type, price, financial position, product portfolio, growth strategies, and regional presence in the global psoriatic arthritis therapeutics market make the report investor’s guide.

Psoriatic Arthritis Therapeutics Market Scope: Inquire before buying

Psoriatic Arthritis Therapeutics Market, by Drug Class

• Nonsteroidal anti-inflammatory drug (NSAID)
• Disease-modifying antirheumatic drug (DMARD)
• Biologic drug
• Enzyme inhibitor
• Interleukin Inhibitors
• Others

Psoriatic Arthritis Therapeutics Market, by Disease Type

• Asymmetric Psoriatic Arthritis
• Symmetric Psoriatic Arthritis
• Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis
• Spondylitis
• Arthritis Mutilans

Psoriatic Arthritis Therapeutics Market, by Distribution Channe

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Psoriatic Arthritis Therapeutics Market, by Route of Administration

• Topical
• Oral
• Injectable

Psoriatic Arthritis Therapeutics Market, by Region

• North America
• Europe
• Asia Pacific
• Middle East & Africa
• South America

Psoriatic Arthritis Therapeutics Market, Key Players

• Pfizer Inc
• Eisai Inc
• UCB Biosciences Inc
• Sanofi
• Otsuka Pharmaceutical
• Sumitomo Dainippon Pharma Co
• Johnson & Johnson
• Celgene Corporation
• AbbVie Inc.
• Novartis AG
• Janssen Biotech
• Eli Lilly and Company
• Biogen Inc.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Amgen Inc.
• AstraZeneca
• Merck & Co

Frequently Asked Questions:

1. Which region has the largest share in Global Psoriatic Arthritis Therapeutics Market?
Ans: North America region holds the highest share in 2021.

2. What is the growth rate of Global Psoriatic Arthritis Therapeutics Market?
Ans: The Global Psoriatic Arthritis Therapeutics Market is growing at a CAGR of 9.5% during forecasting period 2022-2029.

3. What is scope of the Global Psoriatic Arthritis Therapeutics market report?
Ans: Global Psoriatic Arthritis Therapeutics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Psoriatic Arthritis Therapeutics market?
Ans: The important key players in the Global Psoriatic Arthritis Therapeutics Market are – Pfizer Inc, Eisai Inc, UCB Biosciences Inc, Sanofi, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma Co, Johnson & Johnson, Celgene Corporation, AbbVie Inc., Novartis AG, Janssen Biotech, Eli Lilly and Company, Biogen Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Amgen Inc., AstraZeneca, and Merck & Co

5. What is the study period of this market?
Ans: The Global Psoriatic Arthritis Therapeutics Market is studied from 2021 to 2029.

Table of Contents

Global Psoriatic Arthritis Therapeutics Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Psoriatic Arthritis Therapeutics Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast 6.1. Global Psoriatic Arthritis Therapeutics Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Drug Class 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class 7.4. Global Psoriatic Arthritis Therapeutics Market Size (US$ Bn) Forecast, by Drug Class 7.5. Global Psoriatic Arthritis Therapeutics Market Analysis, by Drug Class 7.6. Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Drug Class 8. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Disease Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Disease Type 8.4. Global Psoriatic Arthritis Therapeutics Market Size (US$ Bn) Forecast, by Disease Type 8.5. Global Psoriatic Arthritis Therapeutics Market Analysis, by Disease Type 8.6. Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Disease Type 9. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Distribution Channel 9.4. Global Psoriatic Arthritis Therapeutics Market Size (US$ Bn) Forecast, by Distribution Channel 9.5. Global Psoriatic Arthritis Therapeutics Market Analysis, by Distribution Channel 9.6. Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Distribution Channel 10. Global Psoriatic Arthritis Therapeutics Market Analysis and Forecast, by Route of Administration 10.1. Introduction and Definition 10.2. Key Findings 10.3. Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration 10.4. Global Psoriatic Arthritis Therapeutics Market Size (US$ Bn) Forecast, by Route of Administration 10.5. Global Psoriatic Arthritis Therapeutics Market Analysis, by Route of Administration 10.6. Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Route of Administration 11. Global Psoriatic Arthritis Therapeutics Market Analysis, by Region 11.1. Global Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Region 11.2. Global Psoriatic Arthritis Therapeutics Market Size (US$ Bn) Forecast, by Region 11.3. Global Psoriatic Arthritis Therapeutics Market Attractiveness Analysis, by Region 12. North America Psoriatic Arthritis Therapeutics Market Analysis 12.1. Key Findings 12.2. North America Psoriatic Arthritis Therapeutics Market Overview 12.3. North America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class 12.4. North America Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 12.4.1. Nonsteroidal anti-inflammatory drug (NSAID) 12.4.2. Disease-modifying antirheumatic drug (DMARD) 12.4.3. Biologic drug 12.4.4. Enzyme inhibitor 12.4.5. Interleukin Inhibitors 12.4.6. Others 12.5. North America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Disease Type 12.6. North America Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 12.6.1. Asymmetric Psoriatic Arthritis 12.6.2. Symmetric Psoriatic Arthritis 12.6.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 12.6.4. Spondylitis 12.6.5. Arthritis Mutilans 12.7. North America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Distribution Channel 12.8. North America Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 12.8.1. Hospital Pharmacies 12.8.2. Online Pharmacies 12.8.3. Retail Pharmacies 12.9. North America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration 12.10. North America Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 12.10.1. Topical 12.10.2. Oral 12.10.3. Injectable 12.11. North America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Country 12.12. North America Psoriatic Arthritis Therapeutics Market Forecast, by Country 12.12.1. U.S. 12.12.2. Canada 12.13. North America Psoriatic Arthritis Therapeutics Market Analysis, by Country 12.14. U.S. Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 12.14.1. Nonsteroidal anti-inflammatory drug (NSAID) 12.14.2. Disease-modifying antirheumatic drug (DMARD) 12.14.3. Biologic drug 12.14.4. Enzyme inhibitor 12.14.5. Interleukin Inhibitors 12.14.6. Others 12.15. U.S. Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 12.15.1. Asymmetric Psoriatic Arthritis 12.15.2. Symmetric Psoriatic Arthritis 12.15.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 12.15.4. Spondylitis 12.15.5. Arthritis Mutilans 12.16. U.S. Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 12.16.1. Hospital Pharmacies 12.16.2. Online Pharmacies 12.16.3. Retail Pharmacies 12.17. U.S. Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 12.17.1. Topical 12.17.2. Oral 12.17.3. Injectable 12.18. Canada Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 12.18.1. Nonsteroidal anti-inflammatory drug (NSAID) 12.18.2. Disease-modifying antirheumatic drug (DMARD) 12.18.3. Biologic drug 12.18.4. Enzyme inhibitor 12.18.5. Interleukin Inhibitors 12.18.6. Others 12.19. Canada Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 12.19.1. Asymmetric Psoriatic Arthritis 12.19.2. Symmetric Psoriatic Arthritis 12.19.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 12.19.4. Spondylitis 12.19.5. Arthritis Mutilans 12.20. Canada Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 12.20.1. Hospital Pharmacies 12.20.2. Online Pharmacies 12.20.3. Retail Pharmacies 12.21. Canada Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 12.21.1. Topical 12.21.2. Oral 12.21.3. Injectable 12.22. North America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis 12.22.1. By Drug Class 12.22.2. By Disease Type 12.22.3. By Distribution Channel 12.22.4. By Route of Administration 12.23. PEST Analysis 12.24. Key Trends 12.25. Key Developments 13. Europe Psoriatic Arthritis Therapeutics Market Analysis 13.1. Key Findings 13.2. Europe Psoriatic Arthritis Therapeutics Market Overview 13.3. Europe Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class 13.4. Europe Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 13.4.1. Nonsteroidal anti-inflammatory drug (NSAID) 13.4.2. Disease-modifying antirheumatic drug (DMARD) 13.4.3. Biologic drug 13.4.4. Enzyme inhibitor 13.4.5. Interleukin Inhibitors 13.4.6. Others 13.5. Europe Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Disease Type 13.6. Europe Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 13.6.1. Asymmetric Psoriatic Arthritis 13.6.2. Symmetric Psoriatic Arthritis 13.6.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 13.6.4. Spondylitis 13.6.5. Arthritis Mutilans 13.7. Europe Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Distribution Channel 13.8. Europe Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 13.8.1. Hospital Pharmacies 13.8.2. Online Pharmacies 13.8.3. Retail Pharmacies 13.9. Europe Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration 13.10. Europe Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 13.10.1. Topical 13.10.2. Oral 13.10.3. Injectable 13.11. Europe Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Country 13.12. Europe Psoriatic Arthritis Therapeutics Market Forecast, by Country 13.12.1. Germany 13.12.2. U.K. 13.12.3. France 13.12.4. Italy 13.12.5. Spain 13.12.6. Rest of Europe 13.13. Europe Psoriatic Arthritis Therapeutics Market Analysis, by Country 13.14. Germany Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 13.14.1. Nonsteroidal anti-inflammatory drug (NSAID) 13.14.2. Disease-modifying antirheumatic drug (DMARD) 13.14.3. Biologic drug 13.14.4. Enzyme inhibitor 13.14.5. Interleukin Inhibitors 13.14.6. Others 13.15. Germany Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 13.15.1. Asymmetric Psoriatic Arthritis 13.15.2. Symmetric Psoriatic Arthritis 13.15.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 13.15.4. Spondylitis 13.15.5. Arthritis Mutilans 13.16. Germany Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 13.16.1. Hospital Pharmacies 13.16.2. Online Pharmacies 13.16.3. Retail Pharmacies 13.17. Germany Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 13.17.1. Topical 13.17.2. Oral 13.17.3. Injectable 13.18. U.K. Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 13.18.1. Nonsteroidal anti-inflammatory drug (NSAID) 13.18.2. Disease-modifying antirheumatic drug (DMARD) 13.18.3. Biologic drug 13.18.4. Enzyme inhibitor 13.18.5. Interleukin Inhibitors 13.18.6. Others 13.19. U.K. Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 13.19.1. Asymmetric Psoriatic Arthritis 13.19.2. Symmetric Psoriatic Arthritis 13.19.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 13.19.4. Spondylitis 13.19.5. Arthritis Mutilans 13.20. U.K. Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 13.20.1. Hospital Pharmacies 13.20.2. Online Pharmacies 13.20.3. Retail Pharmacies 13.21. U.K. Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 13.21.1. Topical 13.21.2. Oral 13.21.3. Injectable 13.22. France Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 13.22.1. Nonsteroidal anti-inflammatory drug (NSAID) 13.22.2. Disease-modifying antirheumatic drug (DMARD) 13.22.3. Biologic drug 13.22.4. Enzyme inhibitor 13.22.5. Interleukin Inhibitors 13.22.6. Others 13.23. France Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 13.23.1. Asymmetric Psoriatic Arthritis 13.23.2. Symmetric Psoriatic Arthritis 13.23.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 13.23.4. Spondylitis 13.23.5. Arthritis Mutilans 13.24. France Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 13.24.1. Hospital Pharmacies 13.24.2. Online Pharmacies 13.24.3. Retail Pharmacies 13.25. France Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 13.25.1. Topical 13.25.2. Oral 13.25.3. Injectable 13.26. Italy Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 13.26.1. Nonsteroidal anti-inflammatory drug (NSAID) 13.26.2. Disease-modifying antirheumatic drug (DMARD) 13.26.3. Biologic drug 13.26.4. Enzyme inhibitor 13.26.5. Interleukin Inhibitors 13.26.6. Others 13.27. Italy Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 13.27.1. Asymmetric Psoriatic Arthritis 13.27.2. Symmetric Psoriatic Arthritis 13.27.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 13.27.4. Spondylitis 13.27.5. Arthritis Mutilans 13.28. Italy Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 13.28.1. Hospital Pharmacies 13.28.2. Online Pharmacies 13.28.3. Retail Pharmacies 13.29. Italy Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 13.29.1. Topical 13.29.2. Oral 13.29.3. Injectable 13.30. Spain Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 13.30.1. Nonsteroidal anti-inflammatory drug (NSAID) 13.30.2. Disease-modifying antirheumatic drug (DMARD) 13.30.3. Biologic drug 13.30.4. Enzyme inhibitor 13.30.5. Interleukin Inhibitors 13.30.6. Others 13.31. Spain Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 13.31.1. Asymmetric Psoriatic Arthritis 13.31.2. Symmetric Psoriatic Arthritis 13.31.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 13.31.4. Spondylitis 13.31.5. Arthritis Mutilans 13.32. Spain Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 13.32.1. Hospital Pharmacies 13.32.2. Online Pharmacies 13.32.3. Retail Pharmacies 13.33. Spain Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 13.33.1. Topical 13.33.2. Oral 13.33.3. Injectable 13.34. Rest of Europe Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 13.34.1. Nonsteroidal anti-inflammatory drug (NSAID) 13.34.2. Disease-modifying antirheumatic drug (DMARD) 13.34.3. Biologic drug 13.34.4. Enzyme inhibitor 13.34.5. Interleukin Inhibitors 13.34.6. Others 13.35. Rest of Europe Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 13.35.1. Asymmetric Psoriatic Arthritis 13.35.2. Symmetric Psoriatic Arthritis 13.35.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 13.35.4. Spondylitis 13.35.5. Arthritis Mutilans 13.36. Rest of Europe Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 13.36.1. Hospital Pharmacies 13.36.2. Online Pharmacies 13.36.3. Retail Pharmacies 13.37. Rest Of Europe Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 13.37.1. Topical 13.37.2. Oral 13.37.3. Injectable 13.38. Europe Psoriatic Arthritis Therapeutics Market Attractiveness Analysis 13.38.1. By Drug Class 13.38.2. By Disease Type 13.38.3. By Distribution Channel 13.38.4. By Route of Administration 13.39. PEST Analysis 13.40. Key Trends 13.41. Key Developments 14. Asia Pacific Psoriatic Arthritis Therapeutics Market Analysis 14.1. Key Findings 14.2. Asia Pacific Psoriatic Arthritis Therapeutics Market Overview 14.3. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class 14.4. Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 14.4.1. Nonsteroidal anti-inflammatory drug (NSAID) 14.4.2. Disease-modifying antirheumatic drug (DMARD) 14.4.3. Biologic drug 14.4.4. Enzyme inhibitor 14.4.5. Interleukin Inhibitors 14.4.6. Others 14.5. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Disease Type 14.6. Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 14.6.1. Asymmetric Psoriatic Arthritis 14.6.2. Symmetric Psoriatic Arthritis 14.6.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 14.6.4. Spondylitis 14.6.5. Arthritis Mutilans 14.7. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Distribution Channel 14.8. Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 14.8.1. Hospital Pharmacies 14.8.2. Online Pharmacies 14.8.3. Retail Pharmacies 14.9. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration 14.10. Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 14.10.1. Topical 14.10.2. Oral 14.10.3. Injectable 14.11. Asia Pacific Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Country 14.12. Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Country 14.12.1. China 14.12.2. India 14.12.3. Japan 14.12.4. ASEAN 14.12.5. Rest of Asia Pacific 14.13. Asia Pacific Psoriatic Arthritis Therapeutics Market Analysis, by Country 14.14. China Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 14.14.1. Nonsteroidal anti-inflammatory drug (NSAID) 14.14.2. Disease-modifying antirheumatic drug (DMARD) 14.14.3. Biologic drug 14.14.4. Enzyme inhibitor 14.14.5. Interleukin Inhibitors 14.14.6. Others 14.15. China Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 14.15.1. Asymmetric Psoriatic Arthritis 14.15.2. Symmetric Psoriatic Arthritis 14.15.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 14.15.4. Spondylitis 14.15.5. Arthritis Mutilans 14.16. China Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 14.16.1. Hospital Pharmacies 14.16.2. Online Pharmacies 14.16.3. Retail Pharmacies 14.17. China Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 14.17.1. Topical 14.17.2. Oral 14.17.3. Injectable 14.18. India Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 14.18.1. Nonsteroidal anti-inflammatory drug (NSAID) 14.18.2. Disease-modifying antirheumatic drug (DMARD) 14.18.3. Biologic drug 14.18.4. Enzyme inhibitor 14.18.5. Interleukin Inhibitors 14.18.6. Others 14.19. India Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 14.19.1. Asymmetric Psoriatic Arthritis 14.19.2. Symmetric Psoriatic Arthritis 14.19.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 14.19.4. Spondylitis 14.19.5. Arthritis Mutilans 14.20. India Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 14.20.1. Hospital Pharmacies 14.20.2. Online Pharmacies 14.20.3. Retail Pharmacies 14.21. India Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 14.21.1. Topical 14.21.2. Oral 14.21.3. Injectable 14.22. Japan Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 14.22.1. Nonsteroidal anti-inflammatory drug (NSAID) 14.22.2. Disease-modifying antirheumatic drug (DMARD) 14.22.3. Biologic drug 14.22.4. Enzyme inhibitor 14.22.5. Interleukin Inhibitors 14.22.6. Others 14.23. Japan Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 14.23.1. Asymmetric Psoriatic Arthritis 14.23.2. Symmetric Psoriatic Arthritis 14.23.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 14.23.4. Spondylitis 14.23.5. Arthritis Mutilans 14.24. Japan Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 14.24.1. Hospital Pharmacies 14.24.2. Online Pharmacies 14.24.3. Retail Pharmacies 14.25. Japan Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 14.25.1. Topical 14.25.2. Oral 14.25.3. Injectable 14.26. ASEAN Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 14.26.1. Nonsteroidal anti-inflammatory drug (NSAID) 14.26.2. Disease-modifying antirheumatic drug (DMARD) 14.26.3. Biologic drug 14.26.4. Enzyme inhibitor 14.26.5. Interleukin Inhibitors 14.26.6. Others 14.27. ASEAN Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 14.27.1. Asymmetric Psoriatic Arthritis 14.27.2. Symmetric Psoriatic Arthritis 14.27.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 14.27.4. Spondylitis 14.27.5. Arthritis Mutilans 14.28. ASEAN Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 14.28.1. Hospital Pharmacies 14.28.2. Online Pharmacies 14.28.3. Retail Pharmacies 14.29. ASEAN Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 14.29.1. Topical 14.29.2. Oral 14.29.3. Injectable 14.30. Rest of Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 14.30.1. Nonsteroidal anti-inflammatory drug (NSAID) 14.30.2. Disease-modifying antirheumatic drug (DMARD) 14.30.3. Biologic drug 14.30.4. Enzyme inhibitor 14.30.5. Interleukin Inhibitors 14.30.6. Others 14.31. Rest of Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 14.31.1. Asymmetric Psoriatic Arthritis 14.31.2. Symmetric Psoriatic Arthritis 14.31.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 14.31.4. Spondylitis 14.31.5. Arthritis Mutilans 14.32. Rest of Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 14.32.1. Hospital Pharmacies 14.32.2. Online Pharmacies 14.32.3. Retail Pharmacies 14.33. Rest of Asia Pacific Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 14.33.1. Topical 14.33.2. Oral 14.33.3. Injectable 14.34. Asia Pacific Psoriatic Arthritis Therapeutics Market Attractiveness Analysis 14.34.1. By Drug Class 14.34.2. By Disease Type 14.34.3. By Distribution Channel 14.34.4. By Route of Administration 14.35. PEST Analysis 14.36. Key Trends 14.37. Key Developments 15. Middle East & Africa Psoriatic Arthritis Therapeutics Market Analysis 15.1. Key Findings 15.2. Middle East & Africa Psoriatic Arthritis Therapeutics Market Overview 15.3. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class 15.4. Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 15.4.1. Nonsteroidal anti-inflammatory drug (NSAID) 15.4.2. Disease-modifying antirheumatic drug (DMARD) 15.4.3. Biologic drug 15.4.4. Enzyme inhibitor 15.4.5. Interleukin Inhibitors 15.4.6. Others 15.5. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Disease Type 15.6. Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 15.6.1. Asymmetric Psoriatic Arthritis 15.6.2. Symmetric Psoriatic Arthritis 15.6.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 15.6.4. Spondylitis 15.6.5. Arthritis Mutilans 15.7. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Distribution Channel 15.8. Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 15.8.1. Hospital Pharmacies 15.8.2. Online Pharmacies 15.8.3. Retail Pharmacies 15.9. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration 15.10. Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 15.10.1. Topical 15.10.2. Oral 15.10.3. Injectable 15.11. Middle East & Africa Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Country 15.12. Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Country 15.12.1. GCC 15.12.2. South Africa 15.12.3. Rest of Middle East & Africa 15.13. Middle East & Africa Psoriatic Arthritis Therapeutics Market Analysis, by Country 15.14. GCC Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 15.14.1. Nonsteroidal anti-inflammatory drug (NSAID) 15.14.2. Disease-modifying antirheumatic drug (DMARD) 15.14.3. Biologic drug 15.14.4. Enzyme inhibitor 15.14.5. Interleukin Inhibitors 15.14.6. Others 15.15. GCC Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 15.15.1. Asymmetric Psoriatic Arthritis 15.15.2. Symmetric Psoriatic Arthritis 15.15.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 15.15.4. Spondylitis 15.15.5. Arthritis Mutilans 15.16. GCC Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 15.16.1. Hospital Pharmacies 15.16.2. Online Pharmacies 15.16.3. Retail Pharmacies 15.17. GCC Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 15.17.1. Topical 15.17.2. Oral 15.17.3. Injectable 15.18. South Africa Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 15.18.1. Nonsteroidal anti-inflammatory drug (NSAID) 15.18.2. Disease-modifying antirheumatic drug (DMARD) 15.18.3. Biologic drug 15.18.4. Enzyme inhibitor 15.18.5. Interleukin Inhibitors 15.18.6. Others 15.19. South Africa Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 15.19.1. Asymmetric Psoriatic Arthritis 15.19.2. Symmetric Psoriatic Arthritis 15.19.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 15.19.4. Spondylitis 15.19.5. Arthritis Mutilans 15.20. South Africa Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 15.20.1. Hospital Pharmacies 15.20.2. Online Pharmacies 15.20.3. Retail Pharmacies 15.21. South Africa Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 15.21.1. Topical 15.21.2. Oral 15.21.3. Injectable 15.22. Rest of Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 15.22.1. Nonsteroidal anti-inflammatory drug (NSAID) 15.22.2. Disease-modifying antirheumatic drug (DMARD) 15.22.3. Biologic drug 15.22.4. Enzyme inhibitor 15.22.5. Interleukin Inhibitors 15.22.6. Others 15.23. Rest of Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 15.23.1. Asymmetric Psoriatic Arthritis 15.23.2. Symmetric Psoriatic Arthritis 15.23.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 15.23.4. Spondylitis 15.23.5. Arthritis Mutilans 15.24. Rest of Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 15.24.1. Hospital Pharmacies 15.24.2. Online Pharmacies 15.24.3. Retail Pharmacies 15.25. Rest of Middle East & Africa Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 15.25.1. Topical 15.25.2. Oral 15.25.3. Injectable 15.26. Middle East & Africa Psoriatic Arthritis Therapeutics Market Attractiveness Analysis 15.26.1. By Drug Class 15.26.2. By Disease Type 15.26.3. By Distribution Channel 15.26.4. By Route of Administration 15.27. PEST Analysis 15.28. Key Trends 15.29. Key Developments 16. South America Psoriatic Arthritis Therapeutics Market Analysis 16.1. Key Findings 16.2. South America Psoriatic Arthritis Therapeutics Market Overview 16.3. South America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Drug Class 16.4. South America Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 16.4.1. Nonsteroidal anti-inflammatory drug (NSAID) 16.4.2. Disease-modifying antirheumatic drug (DMARD) 16.4.3. Biologic drug 16.4.4. Enzyme inhibitor 16.4.5. Interleukin Inhibitors 16.4.6. Others 16.5. South America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Disease Type 16.6. South America Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 16.6.1. Asymmetric Psoriatic Arthritis 16.6.2. Symmetric Psoriatic Arthritis 16.6.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 16.6.4. Spondylitis 16.6.5. Arthritis Mutilans 16.7. South America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Distribution Channel 16.8. South America Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 16.8.1. Hospital Pharmacies 16.8.2. Online Pharmacies 16.8.3. Retail Pharmacies 16.9. South America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Route of Administration 16.10. South America Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 16.10.1. Topical 16.10.2. Oral 16.10.3. Injectable 16.11. South America Psoriatic Arthritis Therapeutics Market Value Share Analysis, by Country 16.12. South America Psoriatic Arthritis Therapeutics Market Forecast, by Country 16.12.1. Brazil 16.12.2. Mexico 16.12.3. Rest of South America 16.13. South America Psoriatic Arthritis Therapeutics Market Analysis, by Country 16.14. Brazil Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 16.14.1. Nonsteroidal anti-inflammatory drug (NSAID) 16.14.2. Disease-modifying antirheumatic drug (DMARD) 16.14.3. Biologic drug 16.14.4. Enzyme inhibitor 16.14.5. Interleukin Inhibitors 16.14.6. Others 16.15. Brazil Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 16.15.1. Asymmetric Psoriatic Arthritis 16.15.2. Symmetric Psoriatic Arthritis 16.15.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 16.15.4. Spondylitis 16.15.5. Arthritis Mutilans 16.16. Brazil Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 16.16.1. Hospital Pharmacies 16.16.2. Online Pharmacies 16.16.3. Retail Pharmacies 16.17. Brazil Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 16.17.1. Topical 16.17.2. Oral 16.17.3. Injectable 16.18. Mexico Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 16.18.1. Nonsteroidal anti-inflammatory drug (NSAID) 16.18.2. Disease-modifying antirheumatic drug (DMARD) 16.18.3. Biologic drug 16.18.4. Enzyme inhibitor 16.18.5. Interleukin Inhibitors 16.18.6. Others 16.19. Mexico Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 16.19.1. Asymmetric Psoriatic Arthritis 16.19.2. Symmetric Psoriatic Arthritis 16.19.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 16.19.4. Spondylitis 16.19.5. Arthritis Mutilans 16.20. Mexico Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 16.20.1. Hospital Pharmacies 16.20.2. Online Pharmacies 16.20.3. Retail Pharmacies 16.21. Mexico Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 16.21.1. Topical 16.21.2. Oral 16.21.3. Injectable 16.22. Rest of South America Psoriatic Arthritis Therapeutics Market Forecast, by Drug Class 16.22.1. Nonsteroidal anti-inflammatory drug (NSAID) 16.22.2. Disease-modifying antirheumatic drug (DMARD) 16.22.3. Biologic drug 16.22.4. Enzyme inhibitor 16.22.5. Interleukin Inhibitors 16.22.6. Others 16.23. Rest of South America Psoriatic Arthritis Therapeutics Market Forecast, by Disease Type 16.23.1. Asymmetric Psoriatic Arthritis 16.23.2. Symmetric Psoriatic Arthritis 16.23.3. Distal Interphalangeal Predominant (Dip) Psoriatic Arthritis 16.23.4. Spondylitis 16.23.5. Arthritis Mutilans 16.24. Rest of South America Psoriatic Arthritis Therapeutics Market Forecast, by Distribution Channel 16.24.1. Hospital Pharmacies 16.24.2. Online Pharmacies 16.24.3. Retail Pharmacies 16.25. Rest of South America Psoriatic Arthritis Therapeutics Market Forecast, by Route of Administration 16.25.1. Topical 16.25.2. Oral 16.25.3. Injectable 16.26. South America Psoriatic Arthritis Therapeutics Market Attractiveness Analysis 16.26.1. By Drug Class 16.26.2. By Disease Type 16.26.3. By Distribution Channel 16.26.4. By Route of Administration 16.27. PEST Analysis 16.28. Key Trends 16.29. Key Developments 17. Company Profiles 17.1. Market Share Analysis, by Company 17.2. Competition Matrix 17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 17.2.2. New Product Launches and Product Enhancements 17.2.3. Market Consolidation 17.2.3.1. M&A by Regions, Investment and Applications 17.2.3.2. M&A Key Players, Forward Integration and Backward Integration 17.3. Company Profiles: Key Players 17.3.1. Pfizer Inc 17.3.1.1. Company Overview 17.3.1.2. Financial Overview 17.3.1.3. Portfolio 17.3.1.4. Business Strategy 17.3.1.5. Recent Developments 17.3.1.6. Developing Footprint 17.3.2. Eisai Inc 17.3.3. UCB Biosciences Inc 17.3.4. Sanofi 17.3.5. Otsuka Pharmaceutical 17.3.6. Sumitomo Dainippon Pharma Co 17.3.7. Johnson & Johnson 17.3.8. Celgene Corporation 17.3.9. AbbVie Inc. 17.3.10. Novartis AG 17.3.11. Janssen Biotech 17.3.12. Eli Lilly and Company 17.3.13. Biogen Inc. 17.3.14. Bristol-Myers Squibb Company 17.3.15. Abbott Laboratories 17.3.16. Amgen Inc. 17.3.17. AstraZeneca 17.3.18. Merck & Co 18. Primary Key Insights

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Request Customization Download Sample